This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Keeling D, Tait C, Makris M. Guideline on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. A United Kingdom Haemophilia Center Doctors' Organisation (UKHCDO) guideline approved by the British Committee for Standards in Haematology. Haemophilia 2008; 14(4): 671–84. doi: 10.1111/j.1365-2516.2008.01695.x.KeelingDTaitCMakrisMGuideline on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. A United Kingdom Haemophilia Center Doctors' Organisation (UKHCDO) guideline approved by the British Committee for Standards in HaematologyHaemophilia20081446718410.1111/j.1365-2516.2008.01695.x18422612Open DOISearch in Google Scholar
Department of Health. Government invests an extra £88 million in haemophilia treatments. 12 February 2003. Available at https://webarchive.nationalarchives.gov.uk/20070402232650/http://www.dh.gov.uk/en/Publicationsandstatistics/Pressreleases/DH_4024694 (accessed 28 April 2020).Department of HealthGovernment invests an extra £88 million in haemophilia treatments12February2003Available at https://webarchive.nationalarchives.gov.uk/20070402232650/http://www.dh.gov.uk/en/Publicationsandstatistics/Pressreleases/DH_4024694 (accessed 28 April 2020).Search in Google Scholar
Hay CR. Purchasing factor concentrates in the 21st century through competitive tendering. Haemophilia 2013; 19(5): 660–7. doi: 10.1111/hae.12169.HayCRPurchasing factor concentrates in the 21st century through competitive tenderingHaemophilia2013195660710.1111/hae.1216923711201Open DOISearch in Google Scholar
Harrington C, Hay C, Vidler V, Dattani R, Heygate K. Switching factor products: selecting patients and managing the process. J Haem Pract 2014; 1(2): 24–29. doi: 10.17225/jhp.00021.HarringtonCHayCVidlerVDattaniRHeygateKSwitching factor products: selecting patients and managing the processJ Haem Pract201412242910.17225/jhp.00021Open DOISearch in Google Scholar
Collins P, Chalmers E, Chowdary P, et al. The use of enhanced half-life coagulation factor concentrates in routine clinical practice: guidance from UKHCDO. Haemophilia 2016; 22(4): 487–98. doi: 10.1111/hae.13013.CollinsPChalmersEChowdaryPThe use of enhanced half-life coagulation factor concentrates in routine clinical practice: guidance from UKHCDOHaemophilia20162244879810.1111/hae.1301327311929Open DOISearch in Google Scholar
Khair K, Pollard D, Harrison C, Hook S, O’Driscoll M, Holland M. HOw Patients view Extended half-life products: Impressions from real-world experience (The HOPE study). Haemophilia 2019; 25(5): 814–20. doi: 10.1111/hae.13803.KhairKPollardDHarrisonCHookSO’DriscollMHollandMHOw Patients view Extended half-life products: Impressions from real-world experience (The HOPE study)Haemophilia20192558142010.1111/hae.1380331365176Open DOISearch in Google Scholar
Pollard D, Khair K, Percier C, Wong Y, Shoemark R. Evaluation of MixPro® among users and nurses. J Haem Pract 2017; 5(1): 12–23. doi: doi.org/10.17225/jhp00106PollardDKhairKPercierCWongYShoemarkREvaluation of MixPro® among users and nursesJ Haem Pract2017511223doi: doi.org/10.17225/jhp0010610.17225/jhp00106Search in Google Scholar
Santagostino E, Auerswald G, Benson G, et al. Switching treatments in haemophilia: is there a risk of inhibitor development? Eur J Haematol 2014; 94: 284–89. doi: 10.1111/ejh.12433.SantagostinoEAuerswaldGBensonGSwitching treatments in haemophilia: is there a risk of inhibitor development?Eur J Haematol2014942848910.1111/ejh.12433440793125135593Open DOISearch in Google Scholar
Hay CR, Palmer BP, Chalmers EA, et al. The incidence of factor VIII inhibitors in severe haemophilia A following a major switch from full length to B-domain-deleted factor VIII: a prospective cohort comparison. Haemophilia 2015; 21: 219–26. doi: 10.1111/hae.12563.HayCRPalmerBPChalmersEAThe incidence of factor VIII inhibitors in severe haemophilia A following a major switch from full length to B-domain-deleted factor VIII: a prospective cohort comparisonHaemophilia2015212192610.1111/hae.1256325382829Open DOISearch in Google Scholar
Department of Health & Social Care. The NHS Choice Framework: what choices are available to me in the NHS? 29 April 2016. Available at https://www.gov.uk/government/publications/the-nhs-choice-framework (accessed 28 April 2020).Department of Health & Social CareThe NHS Choice Framework: what choices are available to me in the NHS?29April2016Available at https://www.gov.uk/government/publications/the-nhs-choice-framework (accessed 28 April 2020).Search in Google Scholar
, 